Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Abeona Therapeutics (Nasdaq: ABEO) appointed James A. Gow, MD, MBA, MS, MHCM as Senior Vice President, Head of Clinical Development & Medical Affairs, effective October 20, 2025.
Dr. Gow brings >20 years of industry experience in gene therapy and ophthalmology, having led programs from Phase 1 through post-marketing and contributed to FDA approvals for therapies including Xibrom, Bromday, Prolensa, Bepreve and global approvals for Xiidra. He previously held executive roles at Shire, Takeda, Novartis, Biogen and SparingVision and holds medical and multiple graduate degrees from the University of Manitoba, Cornell and Harvard.
Abeona Therapeutics (Nasdaq: ABEO) ha nominato James A. Gow, MD, MBA, MS, MHCM come Senior Vice President, Head of Clinical Development & Medical Affairs, con effetto dal 20 ottobre 2025.
Il Dr. Gow vanta oltre 20 anni di esperienza nel settore in terapia genica e oftalmologia, avendo guidato programmi dalla fase 1 fino al post-marketing e contribuendo all'approvazione FDA per terapie tra cui Xibrom, Bromday, Prolensa, Bepreve e approvazioni globali per Xiidra. In passato ha ricoperto ruoli esecutivi presso Shire, Takeda, Novartis, Biogen e SparingVision ed è laureato in medicina e titoli di studio post-laurea presso l'Università di Manitoba, Cornell e Harvard.
Abeona Therapeutics (Nasdaq: ABEO) designó a James A. Gow, MD, MBA, MS, MHCM como Vicepresidente Senior, Director de Desarrollo Clínico y Asuntos Médicos, con efectos a partir del 20 de octubre de 2025.
El Dr. Gow aporta más de 20 años de experiencia en la industria en terapia génica y oftalmología, habiendo liderado programas desde la Fase 1 hasta el postcomercialización y contribuido a aprobaciones de la FDA para terapias como Xibrom, Bromday, Prolensa, Bepreve y aprobaciones globales para Xiidra. Anteriormente ocupó cargos ejecutivos en Shire, Takeda, Novartis, Biogen y SparingVision, y posee títulos de medicina y varios grados de posgrado de la Universidad de Manitoba, Cornell y Harvard.
Abeona Therapeutics (Nasdaq: ABEO)는 James A. Gow, MD, MBA, MS, MHCM를 임원진 중 최고 의사결정권 부사장 겸 임상개발 및 의학부문 수장으로 2025년 10월 20일부로 임명했습니다.
고우 박사는 유전자 치료 및 안과 분야에서 20년이 넘는 산업 경력을 보유하고 있으며, 1상에서 시판 후 단계까지의 프로그램을 이끌었고 Xibrom, Bromday, Prolensa, Bepreve 등의 치료제에 대한 FDA 승인 및 Xiidra에 대한 글로벌 승인에 기여했습니다. 그는 이전에 Shire, Takeda, Novartis, Biogen, SparingVision에서 임원직을 역임했으며 매사추세츠주 매니토바 대학교, 코넬 대학교, 하버드 대학교에서 의학 및 다양한 대학원 학위를 취득했습니다.
Abeona Therapeutics (Nasdaq: ABEO) a nommé James A. Gow, MD, MBA, MS, MHCM comme Vice-président principal, Responsable du développement clinique et des affaires médicales, à compter du 20 octobre 2025.
Le Dr Gow apporte plus de 20 ans d'expérience dans l'industrie de la thérapie génique et de l'ophtalmologie, ayant dirigé des programmes de la Phase 1 jusqu'au post-marketing et contribué aux approbations de la FDA pour des thérapies telles que Xibrom, Bromday, Prolensa, Bepreve et des approbations mondiales pour Xiidra. Il occupait précédemment des postes de direction chez Shire, Takeda, Novartis, Biogen et SparingVision, et détient des diplômes de médecine et plusieurs diplômes supérieurs de l'Université du Manitoba, de Cornell et de Harvard.
Abeona Therapeutics (Nasdaq: ABEO) ernannte James A. Gow, MD, MBA, MS, MHCM zum Senior Vice President, Leitender Bereich Klinische Entwicklung & Medizinische Angelegenheiten, mit Wirkung ab dem 20. Oktober 2025.
Dr. Gow bringt über 20 Jahre Branchenerfahrung in Gentherapie und Ophthalmologie mit, er hat Programme von Phase 1 bis Post-Marketing geleitet und an FDA-Zulassungen für Therapien wie Xibrom, Bromday, Prolensa, Bepreve beigetragen sowie globale Zulassungen für Xiidra ermöglicht. Zuvor hatte er Führungspositionen bei Shire, Takeda, Novartis, Biogen und SparingVision inne und besitzt medizinische Abschlüsse und mehrere Graduiertenabschlüsse von der University of Manitoba, Cornell und Harvard.
Abeona Therapeutics (Nasdaq: ABEO) عيّنت James A. Gow, MD, MBA, MS, MHCM نائب الرئيس الأول، رئيس التطوير السريري والشؤون الطبية، اعتباراً من 20 أكتوبر 2025.
يتمتع الدكتور Gow بخبرة صناعية تزيد عن 20 عاماً في العلاج الجيني وطب العيون، حيث قاد برامج من المرحلة الأولى حتى ما بعد التسويق وساهم في موافقات FDA لعلاجات مثل Xibrom, Bromday, Prolensa, Bepreve وتأييد عالمي لـ Xiidra. شغل سابقاً مناصب تنفيذية في Shire, Takeda, Novartis, Biogen وSparingVision، ويمتلك درجات طبية ودرجات عليا متعددة من جامعة مانيتوبا وكورنيل وهارفارد.
Abeona Therapeutics (Nasdaq: ABEO) 任命 James A. Gow, MD, MBA, MS, MHCM 为高级副总裁、临床开发与医学事务部负责人，自2025年10月20日起生效。
Gow博士在基因治疗和眼科领域拥有超过20年的行业经验，领导过从第一阶段到上市后的项目，并参与了包括Xibrom, Bromday, Prolensa, Bepreve在内的疗法的FDA批准，以及全球对Xiidra的批准。他曾在Shire, Takeda, Novartis, Biogen以及SparingVision担任高管，并拥有来自马尼托巴大学、康奈尔大学和哈佛大学的医学及多项研究生学位。
- 20+ years of clinical development and medical affairs experience
- Led programs from Phase 1 through post-marketing
- Track record tied to FDA approvals for multiple ophthalmic drugs
- Appointment effective immediately, adding executive clinical leadership
- No financial guidance or quantified commercial impact provided in the announcement
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately.
"We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has a proven track record of leading novel gene therapy programs for inherited retinal diseases. His addition to our team will be invaluable as we advance our pipeline and deliver transformative treatments to patients."
Dr. Gow has over 20 years of industry experience in clinical development and medical affairs and is a recognized expert in gene therapy, especially in ophthalmology. His track record in clinical development includes leading programs from Phase 1 through post-marketing studies, which led to the FDA approvals of Xibrom, Bromday, Prolensa, Bepreve and global regulatory approvals of Xiidra. Prior to Abeona, Dr. Gow has held executive leadership roles at several pharmaceutical and biotechnology companies, including Shire, Takeda, Novartis, Biogen and SparingVision. Dr. Gow earned his MD from the University of Manitoba, an MBA from Cornell University, a Master of Science in Healthcare Policy and Research from Cornell University, and a Master in Health Care Management from Harvard University.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com
FAQ
Who is James A. Gow and what role did he take at Abeona (ABEO) on October 20, 2025?
What clinical experience does Dr. Gow bring to Abeona (ABEO)?
Which approved drugs are linked to Dr. Gow’s prior clinical leadership before joining Abeona (ABEO)?
Which companies did Dr. Gow work at before joining Abeona (ABEO)?
What is the expected timing for Dr. Gow’s contributions to Abeona’s pipeline (ABEO)?
Did Abeona (ABEO) provide financial or guidance details tied to Dr. Gow’s hire?
